

*(Some content previously found in: BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia and JAK2 and MPL Mutation Analysis in Myeloproliferative Neoplasms Protocols)*

<b>Medical Benefit</b>		<b>Effective Date:</b> 01/01/17	<b>Next Review Date:</b> 11/17
<b>Preauthorization</b>	Yes	<b>Review Dates:</b> 11/16	

***Preauthorization is required for testing for Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms.***

*The following Protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

### Description

In the treatment of Philadelphia chromosome (Ph)-positive leukemias various nucleic acid-based laboratory methods may be used to detect the BCR-ABL1 fusion gene for confirmation of the diagnosis; for quantifying mRNA BCR-ABL1 transcripts during and after treatment to monitor disease progression or remission; and for identification of ABL kinase domain point mutations related to drug resistance when there is inadequate response or loss of response to tyrosine kinase inhibitors (TKIs), or disease progression.

Treatment of acute myeloid leukemia (AML) is based on risk stratification, mainly patient age and tumor cytogenetics. The identification of mutations in several genes, including FLT3, NPM1, and CEBPA, have been proposed to allow for further segregation in the management of this heterogeneous disease.

Acute promyelocytic leukemia (APML, APL) is the M3 subtype of acute myelogenous leukemia (AML), a cancer of the white blood cells. APL is due to a translocation (an exchange of chromosome material) between chromosomes 15 and 17, t(15; 17).

Mutations in the gene encoding Janus kinase 2 (JAK2) protein and in the myeloproliferative leukemia virus oncogene (MPL) encoding the thrombopoietin receptor have been associated with myeloproliferative neoplasms and with acute lymphoblastic leukemia (ALL) in Down syndrome patients.

Approximately 80% of individuals with Chronic Lymphocytic Leukemia exhibit chromosomal aberrations including in genes TP53 and ATM which have been proposed as instructive in management of the disease. A strong relationship has been observed between specific genetic mutations and the clinical course of the disease.

Hairy-cell leukemia (HCL), a rare leukemia, has been associated with the V600E mutation of the BRAF gene.

Classification and treatment of lymphoma may be guided by the identification of mutations which have been associated with specific lymphomas.

In Multiple Myeloma, clinical outcomes have been variable among patients in the same risk category who received similar therapy. Thus, more specific methods have been sought to more finely classify multiple myeloma, including microarray-based gene expression profile (GEP) analysis that shows the underlying activity of

cellular biological pathways that control, for example, cell division or proliferation, apoptosis, metabolism, or other signaling pathways. Microarray-based GEP analysis has been proposed as a means to risk-stratify patients with multiple myeloma to guide treatment decisions.

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) refer to a heterogeneous group of clonal hematopoietic disorders with the potential to transform into acute myelocytic leukemia.

## Policy

### *Acute Lymphocytic Leukemia*

*BCR/ABL1* testing for messenger RNA transcript levels prior to initiation of treatment and during therapy may be considered **medically necessary** for monitoring of Philadelphia chromosome-positive acute lymphocytic leukemia.

Genetic testing in Acute Lymphocytic Leukemia may be **medically necessary** for MLL translocations and IKZF1.

Evaluation of *ABL* kinase domain point mutations is considered **investigational** for monitoring in advance of signs of treatment failure or disease progression.

### *Acute Myeloid Leukemia*

The following may be considered **medically necessary** in Acute Myeloid Leukemia (AML) in patients with normal karyotype:

- Genetic testing for FLT3 internal tandem duplication (FLT3/ITD).
- NPM1 mutations testing.
- Genetic testing of the following genes may be considered **medically necessary** if there is a normal karyotype and FLT3 and NPM1 are normal:
  - KIT
  - DNMT3A
  - CEBPA
  - IDH1/2

The following genetic testing in AML is considered **investigational**:

- Genetic testing for FLT3 internal tandem duplication (FLT3/ITD) and NPM1 mutations.
- Genetic testing for FLT3 tyrosine kinase domain (FLT3/TKD) mutations.
- Genetic testing for FLT3 or NPM1 mutations to detect minimal residual disease.

### *Acute Promyelocytic Leukemia*

Genetic testing for Acute Promyelocytic Leukemia (APML) may be considered **medically necessary**:

- if a diagnosis of APML is suspected but cannot be established by morphological, FISH, or cytogenetic analysis
- for PML/RARalpha, (t (15; 17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis.

### *Chronic Myelogenous Leukemia*

*BCR/ABL1* qualitative testing may be considered **medically necessary** for diagnosis of chronic myeloid leukemia (see Policy Guidelines).

BCR/ABL1 testing for messenger RNA transcript levels (see Policy Guidelines) may be considered **medically necessary** for monitoring of chronic myeloid leukemia treatment response and remission.

Evaluation of ABL kinase domain point mutations to evaluate patients for tyrosine kinase inhibitor resistance may be considered **medically necessary** if there is inadequate initial response to treatment or any sign of loss of response (see Policy Guidelines); and/or when there is progression of the disease to the accelerated or blast phase.

ABL kinase domain mutation testing may be considered **medically necessary** to identify T315I mutation or as a panel (which includes T315I) of the most common and clinically important mutations.

#### *Chronic Lymphocytic Leukemia*

Chromosome deletion analysis may be considered **medically necessary** to determine prognosis by:

- Multi-gene FISH analysis to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence from untreated patients with B-cell CLL to dichotomize CLL (the 13q-, +12, or normal genotype group versus the 11q- or 17p-group).
- Immunoglobulin heavy chain variable region (IGHV or IgVH) gene mutation status.
- ZAP-70 analysis by flow cytometry.

#### *Hairy Cell Leukemia*

Genetic testing for BRAF V600E may be considered **medically necessary** in order to confirm the diagnosis of HCL.

#### *Lymphoma*

Cytogenetic testing may be considered **medically necessary** in the analysis of lymphoma and is the method of choice to detect the following abnormalities that guide classification and treatment:

- T-cell clonality analysis, IGVH analysis, or targeted FISH analysis
- Follicular lymphoma/t(14;18) IgH/BCL2
- Mantle cell lymphoma/t(11;14) IgH/CCND1
- Marginal zone lymphoma/ t(11;18) API/MALT1
- Burkitt lymphoma/t(8;14) IgH/CMYC most commonly or t(2;8) or t(8;22)
- Anaplastic large cell lymphoma/t(2;5) NPM/ALK

#### *Multiple Myeloma*

Microarray-based gene expression profile testing is considered **investigational** in Multiple Myeloma.

#### *Myelodysplastic Syndrome*

Analysis of TET2 may be **medically necessary** to guide the use of hypomethylating agents.

Analysis of TP53 may be considered **medically necessary** to determine prognosis and need for bone marrow transplant.

Multi-gene panel testing in Myelodysplastic Syndrome is considered **investigational**.

#### *Myelofibrosis, Essential Thrombocythemia and Polycythemia Vera*

Genetic testing may be **medically necessary** in patients with suspected myelofibrosis, or essential thrombocythemia, when the diagnosis is unclear after bone marrow morphologic and cytogenetic analysis, to establish a diagnosis in the following situations:

- If BCR-ABL testing is negative it may define a myeloproliferative disease with a distinct leukemia subtype.
- Testing for the Janus Kinase 2 (JAK2; JAK2V617F) gene mutation for the initial diagnostic assessment of adults presenting with clinical, laboratory, or pathological findings suggesting classic forms of polycythemia vera (PV).
- Testing for the Janus Kinase 2 (JAK2; JAK2V617F) gene mutation for the initial diagnostic assessment of BCR-ABL negative adults presenting with clinical, laboratory, or pathological findings suggesting classic forms of essential thrombocythemia (ET) or primary myelofibrosis (PMF).
- MPL Gene Mutations in exon 10.

Testing for the Janus Kinase 2 (JAK2; JAK2V617F) gene mutation is **investigational** for:

- Diagnostic assessment of myeloproliferative disorders (MPD)/myeloproliferative neoplasms (MPN) in children.
- The Quantitative assessment of JAK2V617F allele burden subsequent to qualitative detection of JAK2V617F.

### Medicare Advantage

In addition to or in place of the above policy statements, the following may be considered **medically necessary** to guide therapeutic decision making for Medicare Advantage members:

- In chronic lymphoblastic leukemia (CLL) testing for ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase);
- In acute myeloid leukemia (AML) testing for FLT3/TKD;
- In acute myeloid leukemia (AML) and lymphoma, B-cell testing for the IGH@ (Immunoglobulin heavy chain locus);
- In PDGFRA-associated chronic eosinophilic leukemia testing for PDGFRA (platelet-derived growth factor receptor, alpha polypeptide);
- In Non-Hodgkin's Lymphoma testing for IGH@BCL2 (t (14:18)).

For Medicare Advantage genomic sequencing procedures are considered **not medically necessary**.

### Background

#### *Acute Lymphocytic Leukemia*

ALL is characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs. ALL is the most common childhood tumor, and represents 75% to 80% of acute leukemias in children. ALL represents only 20% of all leukemias in the adult population. Median age at diagnosis is 14 years; 60% of patients are diagnosed at younger than 20 years of age. Current survival rates for patients with ALL have improved dramatically over the past several decades, primarily in children, largely due to better understanding of the molecular genetics of the disease, the incorporation of risk-adapted therapy, and new targeted agents. Current treatment regimens have a cure rate among children of about 80%. The long-term prognosis among adults is poor, with cure rates of 30% to 40%. Prognosis variation is explained, in part, by different subtypes among age groups, including the BCR-ABL fusion gene, which has a poor prognosis and is much less common in childhood ALL.

In ALL, the Ph chromosome is found in 3% of children and 25% to 30% of adults. Two clinically important variants are p190 and p210; p190 is generally associated with acute lymphoblastic leukemia, while p210 is most often seen in CML. The product of BCR-ABL1 is also a functional tyrosine kinase; the kinase domain of the BCR-ABL protein is the same as the kinase domain of the normal ABL protein. However, the abnormal BCR-ABL protein is resistant to normal regulation. Instead, the enzyme is constitutively activated and drives unchecked cellular signal transduction resulting in excess cellular proliferation. Determining the qualitative presence of the BCR-ABL1 fusion gene is not necessary to establish a diagnosis of ALL.

#### Treatment and Response and Minimal Residual Disease

Before initiation of therapy for ALL, quantification of the BCR-ABL transcript is necessary to establish baseline levels for subsequent quantitative monitoring of response during treatment.

Quantitative determination of BCR-ABL1 transcript levels during treatment allows for a very sensitive determination of the degree of patient response to treatment. Evaluation of trial samples has consistently shown that the degree of molecular response correlates with risk of progression. In addition, the degree of molecular response at early time points predicts improved rates of progression-free and event-free survival. Conversely, rising BCR-ABL1 transcript levels predict treatment failure and the need to consider a change in management. With the established poor prognosis of Ph-positive ALL, standard ALL chemotherapy alone has long been recognized as a suboptimal therapeutic option, with 60% to 80% of patients achieving complete response (CR), significantly lower than that achieved in Ph-negative ALL.<sup>4</sup> The inclusion of TKIs to frontline induction chemotherapy has improved CR rates, exceeding 90%.<sup>4</sup>

Treatment response is evaluated initially by hematologic response (normalization of peripheral blood counts), then by cytogenetic response (percent of cells with Ph-positive metaphase chromosomes in a bone marrow aspirate). Complete cytogenetic response (CCyR; 0% Ph-positive metaphases) is expected by six to 12 months after initial treatment with the TKI imatinib.<sup>3</sup>

#### Resistance

Imatinib treatment does not usually result in complete eradication of malignant cells. Not uncommonly, malignant clones resistant to imatinib may be acquired or selected during treatment (secondary resistance), resulting in disease relapse. In addition, a small fraction of chronic phase malignancies that express the fusion gene do not respond to treatment, indicating intrinsic or primary resistance. When the initial response to treatment is inadequate or there is a loss of response, resistance mutation analysis is recommended to support a diagnosis of resistance (based on hematologic or cytogenetic relapse) and to guide the choice of alternative doses or treatments.<sup>3,6</sup>

For patients with increasing levels of BCR-ABL1 transcripts, there is no strong evidence to recommend specific treatment; possibilities include continuation of therapy with dasatinib or nilotinib at the same dose, imatinib dose escalation from 400 mg to 800 mg daily, as tolerated or therapy change to an alternate second-generation TKI.<sup>3</sup>

#### *Acute Myeloid Leukemia*

AML is a group of diverse hematologic malignancies characterized by the clonal expansion of myeloid blasts in the bone marrow, blood, and/or other tissues. It is the most common type of leukemia in adults, and is generally associated with a poor prognosis. It is estimated that, in 2014, 18,860 people will be diagnosed with AML and 10,460 will die of the disease. The median age at diagnosis is 66 years, with approximately one in three patients diagnosed at 75 years of age or older.<sup>1</sup>

#### Diagnosis and Prognosis of AML

The most recent World Health Organization (WHO) classification (2008) reflects the increasing number of acute leukemias that can be categorized based on underlying cytogenetic abnormalities (i.e., at the level of the

chromosome including chromosomal translocations or deletions) or molecular genetic abnormalities (i.e., at the level of the function of individual genes, including gene mutations). These cytogenetic and molecular changes form distinct clinico-pathologic-genetic entities with diagnostic, prognostic, and therapeutic implications.<sup>2</sup> Conventional cytogenetic analysis (karyotyping) is considered to be a mandatory component in the diagnostic evaluation of a patient with suspected acute leukemia, because the cytogenetic profile of the tumor is considered to be the most powerful predictor of prognosis in AML and is used to guide the current risk-adapted treatment strategies. Younger adult patients are usually categorized into three different risk groups based on cytogenetics (good, intermediate, poor risk).

Molecular mutations have been analyzed to subdivide AML with normal cytogenetics into prognostic subsets. In AML, three of the most frequent molecular changes with prognostic impact are mutations of CEBPA encoding a transcription factor, mutations of the FLT3 gene, encoding a receptor of tyrosine kinase involved in hematopoiesis, and mutation of the NPM1 gene, encoding a shuttle protein within the nucleolus. "AML with mutated NPM1 or CEBPA" were included as provisional entities in the 2008 WHO classification of acute leukemias. AML with FLT3 mutations is not considered a distinct entity in the 2008 classification, although WHO recommends determining the presence of FLT3 mutations because of the prognostic significance.<sup>2</sup>

### Treatment

AML has a highly heterogeneous clinical course, and treatment generally depends on the different risk stratification categories.<sup>1</sup>

Genetic testing for cytogenetically normal acute myeloid leukemia is intended to guide management decisions in patients who would receive treatment other than low-dose chemotherapy or best supportive care.

### FLT3 Mutations

FMS-like tyrosine kinase (FLT3) plays a critical role in normal hematopoiesis and cellular growth in hematopoietic stem and progenitor cells. Mutations in FLT3 are one of the most frequently encountered mutations in AML, and approximately 30% of AML patients harbor some form of FLT3 mutation.<sup>6</sup> FLT3 mutations are divided into two categories: (1) internal tandem duplications (FLT3-ITD) mutations, which occur in or near the juxtamembrane domain of the receptor, and (2) point mutations resulting in single amino acid substitutions within the activation loop of the tyrosine kinase domain (FLT3-TKD).

FLT3-ITD mutations are much more common than FLT3-TKD mutations, occurring in 25% of newly diagnosed adult cases of AML, versus FLT3-TKD mutations, occurring in about 7% of patients. FLT3-ITD are a well-documented adverse prognostic marker, particularly in patients younger than 60 years of age and with normal- or intermediate-risk cytogenetics, and is associated with an increased risk of relapse and inferior overall survival (OS).<sup>6-8</sup> Patients with FLT3-ITD mutations have a worse prognosis when treated with conventional chemotherapy, compared with patients with wild-type (WT; i.e., nonmutated) FLT3. Once FLT3-ITD AML relapses, the disease is rapidly fatal.

The prognostic impact of FLT3-TKD mutations is less certain, and has only been studied in small numbers of patients.<sup>6,9</sup> FLT3 tyrosine kinase inhibitors are under active clinical investigation.

### NPM1 Mutations

The most common molecular aberration in AML is a mutation of NPM1, which is found in 46% to 64% of cytogenetically normal AML (CN-AML) and 9% to 18% of cytogenetically abnormal AML.<sup>1</sup> Up to 50% of AML with mutated NPM1 also carry an FLT3-ITD. Mutated NPM1 confers an independent favorable prognosis for patients with CN-AML and either the presence or absence of an FLT3-ITD. Retrospective studies of banked clinical samples suggest that an NPM1 mutation may mitigate the negative prognostic effect of an FLT3-ITD, but possibly only if the FLT3-ITD to WT allelic ratio is low.<sup>6</sup> The prognostic impact in patients with an abnormal karyotype is unclear.<sup>1</sup>



### CEBPA Mutations

CEBPA (CCAAT/enhancer binding protein) is a transcription-factor gene that plays a role in cell cycle regulation and cell differentiation. Mutations to CEBPA are found in approximately 15% of AML patients with a normal karyotype.<sup>10-12</sup> CEBPA mutations can be either biallelic (double mutations) or monoallelic. Monoallelic mutations are prognostically similar to CEBPA WT and do not confer a favorable prognosis in cytogenetically normal AML; double mutations of CEBPA have shown a better prognosis with higher rates of CR and OS after standard induction chemotherapy.<sup>13, 14</sup>

### Acute Promyelocytic Leukemia

APL is a form of AML. In APL, there is an abnormal accumulation of promyelocytes and a deficiency of mature red blood cells in the myeloid line of cells. This disease occurs in approximately one in 250,000 people in the United States and accounts for about 10% of AML diagnosis. APL usually occurs in middle-aged adults and responds favorably to treatments including retinoids, chemotherapy and, most recently, arsenicals.

This somatic mutation occurs as a translocation between chromosomes 15 and 17, t (15; 17), fusing part of the PML gene with part of the RARA gene. The protein produced from this fused gene is known as PML-RAR $\alpha$  and produces a different effect, interfering with the normal function of both than the PML and the RAR $\alpha$  proteins. As a result, white blood cells (WBCs) fail to mature appropriately beyond the promyelocyte stage, growing and dividing too rapidly so that they accumulate excessively in the bone marrow and prevent normal WBCs from developing. The PML-RARA gene fusion accounts for up to 98 percent of cases of APL. Translocations involving the RARA gene and other genes have been identified in a few cases of APL.

### Chronic Myelogenous Leukemia

CML is a clonal disorder of myeloid hematopoietic stem cells, accounting for 15% of adult leukemias. The disease occurs in chronic, accelerated, and blast phases, but is most often diagnosed in the chronic phase. If left untreated, chronic phase disease will progress within three to five years to the accelerated phase, characterized by any of several specific criteria such as 10% to 19% blasts in blood or bone marrow, basophils comprising 20% or more of the white blood cell count, very high or very low platelet counts, etc.<sup>1</sup> From the accelerated phase, the disease progresses into the final phase of blast crisis, in which the disease behaves like an acute leukemia, with rapid progression and short survival. Blast crisis is diagnosed by the presence of either more than 20% myeloblasts or lymphoblasts in the blood or bone marrow, large clusters of blasts in the bone marrow on biopsy, or development of a solid focus of leukemia outside the bone marrow.

Although CML is diagnosed primarily by clinical and cytogenetic methods, qualitative molecular testing is needed to confirm the presence of the BCR-ABL1 fusion gene, particularly if the Ph chromosome was not found and to identify the type of fusion gene, as this information is necessary for subsequent quantitative testing of fusion gene messenger RNA transcripts. If the fusion gene is not confirmed, then the diagnosis of CML is called into question.

Extensive clinical data have led to the development of congruent recommendations and guidelines developed both in North America and in Europe concerning the use of various types of molecular tests relevant to the diagnosis and management of CML. These tests are also useful in the accelerated and blast phases of this malignancy.

Imatinib (Gleevec®) a TKI, was originally developed to specifically target and inactivate the Abl tyrosine kinase portion of the BCR-ABL1 fusion protein to treat patients with CML. In patients with chronic phase CML, early imatinib study data indicated a high response rate to imatinib compared with standard therapy, and long-term follow-up has shown that continuous treatment of chronic phase CML results in “durable responses in [a] large proportion of the patients with a decreasing rate of relapse.”<sup>3</sup> As a result, imatinib became the primary therapy for most patients with newly diagnosed chronic phase CML.

For CML, testing is appropriate at baseline before the start of imatinib treatment and testing is appropriate every three months when the patient is responding to treatment. After a complete cytogenetic response is achieved, testing is recommended every three months for two years and then every three to six months thereafter.

Without complete cytogenetic response, continued monitoring at three-month intervals is recommended. It has been assumed that the same time points for monitoring imatinib are appropriate for dasatinib and nilotinib as well and will likely also be applied to bosutinib and ponatinib.

#### *Chronic Lymphocytic Leukemia*

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world, accounting for approximately 30% of all leukemia diagnosis in the United States, with an incidence of three to five cases per 100,000. It has a tremendously variable clinical course so that survival ranges from months to years. The median age at diagnosis of CLL is approximately 72 years, but it may present in younger individuals, often as poor-risk disease with significantly reduced life expectancy.

Chronic lymphocytic leukemia (CLL) is a neoplasm of hematopoietic origin characterized by the accumulation of lymphocytes with a mature, generally well-differentiated morphology. In CLL, these cells accumulate in blood, bone marrow, lymph nodes, and spleen.

CLL tends to present as asymptomatic enlargement of the lymph nodes, and is indolent in nature although it can undergo transformation to a more aggressive form of disease (e.g., Richter transformation). Low- and intermediate-risk CLL demonstrates relatively good prognoses with median survivals of six to 10 years; however, the median survival of high-risk CLL may only be two years. Although typically responsive to initial therapy, CLL is rarely cured by conventional therapy, and nearly all patients ultimately die of their disease.

#### *Hairy Cell Leukemia*

Hairy Cell Leukemia is classified as a Mature B-Cell Neoplasm, this rare disease is so named for the appearance of B-lymphocytes which have hair like projections when viewed under a microscope. Hairy cell leukemia is a chronic disease with no generally accepted staging system. It accounts for approximately 2% of leukemia diagnosis annually in the United States, about 600-800 cases. Typically women are less likely to be affected than men, and middle aged or older adults are most at risk.

Remission is often possible and most likely longstanding. Although relapse is likely remission may be achievable more than once with survival frequently for 10 years or longer after diagnosis. The etiology of HCL is unknown, although it has been recognized that BRAF V600E mutation is present in most individuals with this disease. Vemurafenib is a drug which targets the effects of BRAF mutations and has been reported to promote a positive response in HCL, including for those with relapsed or refractory disease.

#### *Lymphomas*

According to the updated WHO Classification 2008<sup>5</sup> the following are classified as Mature B-Cell Neoplasms: Hairy cell leukemia, Mantle cell lymphoma, Follicular lymphoma, Splenic marginal zone lymphoma, Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone B-cell lymphoma (MZL), B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In the United States, B-cell lymphomas represent 80% to 85% of cases of Non-Hodgkins Lymphoma.

In general, NHL can be divided into two prognostic groups, indolent and aggressive. Indolent NHL has a relatively good prognosis, with a median survival of 10 years; however, it is not curable in advanced clinical stages.<sup>2</sup> Early stage indolent NHL (stage 1 or 2) may be effectively treated with radiation alone.<sup>2</sup> Although indolent NHL is responsive to radiation and chemotherapy, a continuous rate of relapse is seen in advanced stages.<sup>2</sup> These



patients can often be retreated if their disease remains of the indolent type. Indolent NHL may transform into a more aggressive form, which is generally treated with regimens that are used for aggressive, recurrent NHL. Histologic transformation to higher grade lymphoma occurs in up to 70% of patients with low-grade lymphoma,<sup>7</sup> and median survival with conventional chemotherapy is one year or less.

Follicular Lymphoma (FL) is the most common indolent NHL (70%-80% of cases), and often the terms indolent lymphoma and FL are used synonymously. Also included in the indolent NHL are SLL/CLL, lymphoplasmacytic lymphoma, marginal zone lymphomas, and cutaneous T-cell lymphoma.

Aggressive NHL has a shorter natural history; however, 30% to 60% of these patients can be cured with intensive combination chemotherapy regimens.<sup>2</sup> Aggressive lymphomas include DLBCL, MCL, PTCL, anaplastic large cell lymphoma, and Burkitt lymphoma.

Mantle Cell Lymphoma (MCL) comprises approximately 65% to 68% of NHL and has been recognized within the past 15 years as a unique lymphoma subtype with a particularly aggressive course. MCL is characterized by a chromosomal translocation t(11;14), and the term mantle cell lymphoma was proposed in 1992 by Banks et al.<sup>10</sup> MCL shows a strong predilection for elderly men, and most cases (70%) present with disseminated (stage 4) disease and extranodal involvement is common. Localized MCL is quite rare. MCL has a median survival of approximately two to four years, and although most patients achieve remission with first-line therapy, relapse inevitably occurs, often within 12 to 18 months. MCL is rarely, if ever, cured with conventional therapy, and no standardized therapeutic approach to MCL is used.

#### *Multiple Myeloma*

Multiple myeloma is a malignant plasma-cell dyscrasia characterized by clonal proliferation of plasma cells derived from B cells in the bone marrow.<sup>11</sup> It accounts for about one in every 100 cancers and 13% of hematologic cancers. The annual age-adjusted incidence is about six cases per 100,000 persons, with median age at diagnosis of about 70 years. Before the advent of current treatment protocols, most patients with multiple myeloma succumbed to their disease within five to 10 years; in the prechemotherapy era, median survival was less than one year. Among patients who present at an age younger than 60 years, 10-year overall survival with current treatment protocols now may exceed 30%.<sup>13</sup>

A host of well-characterized factors related to tumor biology, tumor burden, and patient-centered characteristics are used to stratify patients into high, intermediate, and standard risk categories for purposes of prognostication and to determine treatment intensity.

Asymptomatic (smoldering) multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) currently require only ongoing clinical observation, because early treatment with conventional chemotherapy has shown no benefit. However, for symptomatic patients diagnosed with multiple myeloma, prompt induction therapy is indicated. Despite achievement of complete remission and apparent eradication of disease, the clinical response is transitory in all cases, and multiple myeloma is considered incurable with current approaches.

#### *Myelodysplastic Syndromes/Myeloproliferative Neoplasms*

Myelodysplastic syndromes (MDS) can occur as a primary (idiopathic) disease or can be secondary to cytotoxic therapy, ionizing radiation, or other environmental insult. Chromosomal abnormalities are seen in 40% to 60% of patients, frequently involving deletions of chromosome 5 or 7, or an extra chromosome as in trisomy 8. Most MDS diagnoses occur in individuals older than age 55 to 60 years, with an age adjusted incidence of approximately 62% among individuals older than age 70 years. Patients either succumb to disease progression to acute myeloid leukemia (AML) or to complications of pancytopenias. Patients with higher blast counts or complex cytogenetic abnormalities have a greater likelihood of progressing to AML than do other patients.

Treatment of smoldering or nonprogressing MDS has involved best supportive care, including red blood cell (RBC) and platelet transfusions and antibiotics. Active therapy was given only when MDS progressed to AML or resembled AML with severe cytopenias. Given the spectrum of treatments available, the goal of therapy must be decided upfront whether it is to improve anemia; thrombocytopenia; or neutropenia, eliminate the need for RBC transfusion, achieve complete remission, or cure the disease.

Allo-HSCT is the only approach with curative potential, but its use is governed by patient age, performance status, medical comorbidities, the patient's risk preference, and severity of MDS at presentation.

#### *Chronic Myeloproliferative Neoplasms*

Chronic myeloproliferative neoplasms (MPN) are clonal bone marrow stem cell disorders; as a group, approximately 8400 MPN are diagnosed annually in the United States. Like MDS, MPN primarily occur in older individuals, with approximately 67% reported in patients aged 60 years and older.

MPNs are characterized by the slow but relentless expansion of a clone of cells with the potential evolution into a blast crisis similar to AML. MPN share a common stem cell–derived clonal heritage, with phenotypic diversity attributed to abnormal variations in signal transduction as the result of a spectrum of mutations that affect protein tyrosine kinases or related molecules. The unifying characteristic common to all MPN is effective clonal myeloproliferation resulting in peripheral granulocytosis, thrombocytosis, or erythrocytosis that is devoid of dyserythropoiesis, granulocytic dysplasia, or monocytosis.

In indolent, nonprogressing cases, therapeutic approaches are based on relief of symptoms. Supportive therapy may include prevention of thromboembolic events. Hydroxyurea may be used in cases of high-risk essential thrombocytosis and polycythemia vera, and intermediate- and high-risk primary myelofibrosis.

In November 2011, FDA approved the orally administered selective Janus kinase 1 and 2 inhibitor ruxolitinib for the treatment of intermediate- or high-risk myelofibrosis.

Myeloablative allo-HSCT has been considered the only potentially curative therapy, but because most patients are of advanced age with attendant comorbidities, its use is limited to those who can tolerate the often severe treatment-related adverse effects of this procedure. However, use of RIC of conditioning regimens for allo-HSCT has extended the potential benefits of this procedure to selected individuals with these disorders.

#### *MPNs*

MPNs are uncommon overlapping blood diseases characterized by the production of one or more blood cell lines and include chronic myeloid leukemia (CML), PV, ET, PMF, systemic mastocytosis, chronic eosinophilic leukemia, and others. A common finding in many MPNs is clonality, and a central pathogenic feature is a mutated version of a tyrosine kinase enzyme, such that it is abnormally constitutively activated. The paradigm for use of this information to revolutionize patient management is CML. A unique chromosomal change (Ph) and an accompanying unique gene rearrangement (*BCR-ABL*) resulting in a continuously activated tyrosine kinase enzyme were identified. These findings led to the development of targeted tyrosine kinase inhibitor drug therapy (imatinib) that produces long-lasting remissions.

Diagnosis and monitoring of patients with Ph-negative MPNs have been challenging because many of the laboratory and clinical features of the classic forms of these diseases—PV, ET, and PMF—can be mimicked by other conditions such as reactive or secondary erythrocytosis, thrombocytosis, or myeloid fibrosis. Additionally, these entities can be difficult to distinguish on morphologic bone marrow exam, and diagnosis can be complicated by changing disease patterns: PV and ET can evolve into PMF or undergo leukemic transformation. World Health Organization criteria were published as a benchmark for diagnosis in 2001<sup>1</sup> and updated in 2008.<sup>2</sup> These have been challenging to use because they involve complex diagnostic algorithms, rely on morphologic assessment of uncertain consistency, and require tests that are not well-standardized or widely available, such as endogenous erythroid colony formation.

Although identifying specific mutations was of importance in better understanding the biology of MPNs, they also were of immediate interest as laboratory tools to aid in diagnosis and management of disease. To that end, at least four potential intended uses for mutation testing have been considered, including:

- a. Diagnosis of patients with clinical, laboratory, or pathologic findings suggesting classic MPNs (PV, ET, or PMF);
- b. Diagnosis or selection of treatment for patients with Down syndrome ALL;
- c. Phenotyping of disease subtypes in patients with MPNs to establish disease prognosis;
- d. Identification, selection, and monitoring of treatment.

Many diagnostic procedures are available for *JAK2* testing and *MPL* mutation testing. Variable analytic and clinical performance has been reported, suggesting that nucleic acid amplification methodologies are more sensitive than mutation sequence analysis. It appears that there can be considerable interassay and interlaboratory variability in testing results.

### Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). The BCR/ABL1 qualitative and quantitative genotyping tests, and ABL KD mutation tests, are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

More than a dozen commercial laboratories currently offer a wide variety of diagnostic procedures for *JAK2* testing and *MPL* mutation testing.

Clinically validated FLT3 mutation testing is performed with a polymerase chain reaction–based assay of genomic DNA isolated from the leukemic cells, either from blood or bone marrow. Testing for FLT3 may involve a duplex assay, which tests for both types of FLT3 mutations (ITD and TKD), however, some laboratories only test for ITD mutations, as the prognostic effect of TKD mutations is uncertain.<sup>6</sup> Several Laboratories offer these tests.

### Related Protocols

Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this Protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*. Oct 1 2002; 100(7):2292-2302. PMID 12239137
2. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program*. 2012; 2012:389-396. PMID 23233609
3. NCCN. NCCN Guidelines v.1.2015 Chronic Myelogenous Leukemia. [http://www.nccn.org/professionals/physician\\_gls/pdf/cml.pdf](http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf). Accessed January 21, 2015.
4. Fielding AK, Zakout GA. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Curr Hematol Malig Rep*. Jun 2013; 8(2):98-108. PMID 23475624
5. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med*. Jun 17 2010; 362(24):2251-2259. PMID 20525993
6. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. Jun 17 2010; 362(24):2260-2270. PMID 20525995
7. Mughal TI, Goldman JM. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. *Clin Lymphoma Myeloma*. Mar 2007; 7 Suppl 2:S81-84. PMID 17382017
8. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. *Leukemia*. Oct 2006; 20(10):1767-1773. PMID 16855631
9. von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). *Blood*. Aug 15 2006; 108(4):1328-1333. PMID 16614241
10. le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. *Leukemia*. Jun 2012; 26(6):1189-1194. PMID 22076466
11. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). *Crit Rev Oncol Hematol*. Feb 2006; 57(2):145-164. PMID 16213151
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*. Dec 7 2006; 355(23):2408-2417. PMID 17151364
13. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. *Blood*. Jun 18 2009; 113(25):6315-6321. PMID 19369233
14. Müller MC, Hanfstein B, Erben P, et al. Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV. *Blood* 2008; 112:129. Abstract 333. PMID
15. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *J Clin Oncol*. Dec 10 2009; 27(35):6041-6051. PMID 19884523

16. Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? *Br J Haematol*. May 2009; 145(3):373-375. PMID 19344397
17. National Comprehensive Cancer Network. Practice Guidelines in Oncology v.1.2015 Chronic Myelogenous Leukemia. <http://www.nccn.org/>. Accessed January 21, 2015.
18. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. *Best Pract Res Clin Haematol*. Sep 2009; 22(3):355-365. PMID 19959086
19. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood*. Apr 22 2010; 115(16):3206-3214. PMID 20154213
20. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. American Society of Hematology 54th Annual Meeting, December 2012. 2012:Abstract 163. PMID
21. Houry HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. *Blood*. Apr 12 2012; 119(15):3403-3412. PMID 22371878
22. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. *Blood*. Oct 27 2011; 118(17):4567-4576. PMID 21865346
23. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. *N Engl J Med*. Nov 29 2012; 367(22):2075-2088. PMID 23190221
24. Ernst T, Gruber FX, Pelz-Ackermann O, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. *Haematologica*. Sep 2009; 94(9):1227-1235. PMID 19608684
25. National Comprehensive Cancer Network. NCCN Guidelines v.2.2014 Acute Lymphoblastic Leukemia. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#site](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site). Accessed January 21, 2015.
26. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. *Leukemia*. Mar 2010; 24(3):521-535. PMID 20033054
27. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. Jul 30 2009; 114(5):937-951. PMID 19357394
28. Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. *Leuk Lymphoma*. Sep 1996; 22 Suppl 1:87-93. PMID 8951778
29. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. *Cancer*. Sep 1 2009; 115(17):3842-3847. PMID 19472396
30. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. Mar 19-25 2005; 365(9464):1054-1061. PMID 15781101

31. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. Apr 2005; 7(4):387-397. PMID 15837627
32. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. Apr 28 2005; 434(7037):1144-1148. PMID 15793561
33. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. *Blood*. Sep 15 2005; 106(6):2162-2168. PMID 15920007
34. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. *J Biol Chem*. Jun 17 2005; 280(24):22788-22792. PMID 15863514
35. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. *Lancet*. Dec 3 2005; 366(9501):1945-1953. PMID 16325696
36. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. *Blood*. Mar 1 2006; 107(5):2098-2100. PMID 16293597
37. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. *Br J Haematol*. Nov 2005; 131(3):320-328. PMID 16225651
38. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. *Leukemia*. Feb 2006; 20(2):350-353. PMID 16341032
39. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. *Br J Haematol*. Sep 2007; 138(6):821-822. PMID 17672880
40. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood*. Aug 15 2007; 110(4):1092-1097. PMID 17488875
41. Kondo T, Okuno N, Naruse H, et al. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. *Leuk Lymphoma*. Sep 2008; 49(9):1784-1791. PMID 18661406
42. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. *Blood*. Aug 15 2005; 106(4):1207-1209. PMID 15860661
43. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *N Engl J Med*. Feb 1 2007; 356(5):459-468. PMID 17267906
44. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2 V617F-negative polycythemia vera. *Leukemia*. Sep 2007; 21(9):1960-1963. PMID 17597810
45. Siemiatkowska A, Bieniaszewska M, Hellmann A, et al. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. *Leuk Res*. Mar 2010; 34(3):387-389. PMID 19643476
46. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med*. Jul 2006; 3(7):e270. PMID 16834459
47. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood*. Nov 15 2006; 108(10):3472-3476. PMID 16868251
48. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood*. Jul 1 2008; 112(1):141-149. PMID 18451306



49. Schnittger S, Bacher U, Haferlach C, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. *Haematologica*. Jan 2009; 94(1):141-144. PMID 19029146
50. Malinge S, Ben-Abdelali R, Settegrana C, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. *Blood*. Mar 1 2007; 109(5):2202-2204. PMID 17068151
51. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet*. Oct 25 2008; 372(9648):1484-1492. PMID 18805579
52. Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. *Br J Haematol*. Mar 2009; 144(6):930-932. PMID 19120350
53. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. *Blood*. Aug 1 2007; 110(3):840-846. PMID 17379742
54. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 (V617F) allele burden. *Leukemia*. Sep 2007; 21(9):1952-1959. PMID 17625606
55. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2 V617F allele burden and clinical correlates in polycythemia vera. *Leukemia*. Sep 2007; 21(9):2074-2075. PMID 17476276
56. Panani AD. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications. *Cancer Lett*. Oct 18 2009; 284(1):7-14. PMID 19269737
57. Valla DC. Primary Budd-Chiari syndrome. *J Hepatol*. Jan 2009; 50(1):195-203. PMID 19012988
58. Mannucci PM, Peyvandi F. Thrombophilia screening: little role for the JAK2 V617F mutation. *Mayo Clin Proc*. Apr 2008; 83(4):398-399. PMID 18380984
59. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. *Blood*. Jun 2 2011; 117(22):5857-5859. PMID 21490340
60. Tefferi A, Lasho TL, Huang J, et al. Low JAK2 V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. *Leukemia*. Apr 2008; 22(4):756-761. PMID 18216871
61. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. *Blood*. Dec 1 2007; 110(12):4030-4036. PMID 17712047
62. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2 V617F mutated allele. *Blood*. Aug 20 2009; 114(8):1477-1483. PMID 19549988
63. Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. *Leukemia*. Oct 2013; 27(10):2032-2039. PMID 23860450
64. Bench AJ, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. *Br J Haematol*. Jan 2013; 160(1):25-34. PMID 23057517

65. Fantasia F, Di Capua EN, Cenfra N, et al. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2 V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. *Ann Hematol*. Oct 31 2013. PMID 24173087
66. Furtado LV, Weigelin HC, Elenitoba-Johnson KS, et al. Detection of MPL mutations by a novel allele-specific PCR-based strategy. *J Mol Diagn*. Nov 2013; 15(6):810-818. PMID 23994117
67. Topkaya SN, Kosova B, Ozsoz M. Detection of Janus Kinase 2 gene single point mutation in real samples with electrochemical DNA biosensor. *Clin Chim Acta*. Dec 12 2013; 429C:134-139. PMID 24333614
68. Kumar C, Purandare AV, Lee FY, et al. Kinase drug discovery approaches in chronic myeloproliferative disorders. *Oncogene*. Jun 18 2009; 28(24):2305-2313. PMID 19421140
69. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. *N Engl J Med*. Sep 16 2010; 363(12):1117-1127. PMID 20843246
70. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *Blood*. Feb 11 2010; 115(6):1131-1136. PMID 20008298
71. Quintas-Cardama A, Verstovsek S. Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. *Cancer*. Jul 15 2012; 118(4):870-877. PMID 21766300
72. Antonioli E, Carobbio A, Pieri L, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. *Haematologica*. Aug 2010; 95(8):1435-1438. PMID 20418246
73. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. Mar 1 2012; 366(9):799-807. PMID 22375971
74. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelo-fibrosis. *N Engl J Med*. Mar 1 2012; 366(9):787-798. PMID 22375970
75. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. *Mayo ClinProc*. Apr 2013; 88(4):360-376. PMID 23541011
76. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood*. May 5, 2011; 117(18):4696-4700. PMID 21292777
77. Johnson SK, Heuck CJ, Albino AP, et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. *Int J Hematol*. Oct 2011; 94(4):321-333. PMID 22002477
78. Zhou Y, Barlogie B, Shaughnessy JD, Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. *Leukemia*. Nov 2009; 23(11):1941-1956. PMID 19657360
79. Matsui S, Simon R, Qu P, et al. Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. *Clin Cancer Res*. Nov 1 2012; 18(21):6065-6073. PMID 22927484
80. Meissner T, Seckinger A, Reme T, et al. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine. *Clin Cancer Res*. Dec 1 2011; 17(23):7240-7247. PMID 21986844
81. Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med*. Mar 17 2011; 364(11):1046-1060. PMID 21410373

82. American Cancer Society. Multiple Myeloma. 2012; <http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics>. Accessed August 6, 2015.
83. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia*. Jan 2009; 23(1):3-9. PMID 18971951
84. Blade J, Dimopoulos M, Rosinol L, et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. *J Clin Oncol*. Feb 1 2010; 28(4):690-697. PMID 20026810
85. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. *Nat Rev Cancer*. May 2012; 12(5):335-348. PMID 22495321
86. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. Jun 2010; 24(6):1121-1127. PMID 20410922
87. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia*. Dec 2009; 23(12):2210-2221. PMID 19798094
88. Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. *Clin Cancer Res*. Mar 15 2011; 17(6):1234-1242. PMID 21411439
89. Kumar SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*. Oct 20 2011; 118(16):4359-4362. PMID 21860025
90. Papanikolaou X, Alapat D, Rosenthal A, et al. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. *Leukemia*. Aug 2015; 29(8):1713-1720. PMID 25753926
91. Amin SB, Yip WK, Minvielle S, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. *Leukemia*. Nov 2014; 28(11):2229-2234. PMID 24732597
92. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. *Leukemia*. Feb 2014; 28(2):269-277. PMID 23974982
93. Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. *Expert Review of Hematology*. 2014; 7(1):21-31.
94. National Comprehensive Cancer Network (NCCN). Multiple Myeloma V 4.2015. [http://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed August 6, 2015.
95. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. Jun 15 2008; 111(12):5446-5456. PMID 18216293
96. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. *Blood*. 1994; 84(5):1361-1392.
97. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Arlie House, Virginia, 1997. *J Clin Oncol*. 1999; 17(12):3835.

98. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. *Hematology* 2009:523-531.
99. Non-Hodgkin's Lymphomas. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. v5.2014; [http://www.nccn.org/professionals/physician\\_gls/PDF/nhl.pdf](http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf). Accessed December 12, 2014. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *N Engl J Med*. Sep 30 1993; 329(14):987-994. PMID 8141877
100. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood*. 2004; 104(5):1258-1265